Survival Outcomes of an Irinotecan, Temozolomide, Dinutuximab, GM-CSF Regimen in Patients With Relapsed High-Risk Neuroblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor
J. Clin. Oncol 2022 Oct 07;[EPub Ahead of Print], BJ Lerman, Y Li, C Carlowicz, M Granger, T Cash, A Sadanand, K Somers, A Ranavaya, BD Weiss, M Choe, JH Foster, N Pinto, DA Morgenstern, MS Rafael, KA Streby, RN Zeno, R Mody, S Yazdani, AV Desai, ME Macy, S Shusterman, SM Federico, R BagatellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.